New Zealand markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
66.16-0.77 (-1.15%)
At close: 04:00PM EDT
66.66 +0.50 (+0.76%)
After hours: 07:53PM EDT

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650 574 3000
https://www.gilead.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees18,000

Key executives

NameTitlePayExercisedYear born
Mr. Daniel P. O'DayChairman & CEO6.99MN/A1964
Mr. Andrew D. DickinsonChief Financial Officer2.66MN/A1970
Ms. Deborah H. TelmanExecutive VP of Corporate Affairs, General Counsel & Corporate Secretary2.56MN/A1965
Ms. Johanna MercierChief Commercial Officer3.1MN/A1970
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer2.79MN/A1964
Ms. Sandra PattersonSenior VP, Corporate Controller & Principal Accounting OfficerN/AN/A1967
Ms. Jacquie Ross C.F.A.Vice President of Investor RelationsN/AN/AN/A
Ms. Jyoti K. MehraExecutive Vice President of Human ResourcesN/AN/A1976
Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & PortfolioN/AN/A1962
Dr. Rudolf ErtlSenior Vice President of Commercial Operations of Australia, Canada, EuropeN/AN/A1946
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Corporate governance

Gilead Sciences, Inc.’s ISS governance QualityScore as of 1 April 2024 is 1. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.